DOCSLIB.ORG

Thesis Template

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Thesis Template Pharmacogovernance in Low- and Middle-Income Countries: a case study of Brazil and Kenya by Kathy Moscou A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Pharmaceutical Sciences University of Toronto © Copyright by Kathy Moscou 2016 Pharmacogovernance in Low- and Middle-Income Countries: a case study of Brazil and Kenya Kathy Moscou Doctor of Philosophy Department of Pharmaceutical Sciences University of Toronto 2016 Abstract Adverse drug reactions (ADRs) are a global public health threat leading to illness, disability and death. Yet, few countries have a framework to guide postmarket drug safety policy despite increasing access to pharmaceuticals worldwide and the growing trend of gathering information about medicines in the postmarket (rather than the premarket) period. This gap is addressed by ‘pharmacogovernance’, a new theoretical concept that is introduced in this thesis. Pharmacogovernance is defined as the manner in which governing structures; policy instruments; and institutional authority (e.g., ability to act, implement and enforce norms, policies and processes) are managed to promote societal interests for patient safety and protection from ADRs. An analytic framework for examining pharmacogovernance is presented that clarifies the relationship between governance and pharmacovigilance in order to explain how pharmacogovernance influences pharmacovigilance. The research investigates how and why the State (at all levels), global actors and the pharmaceutical industry interact to affect pharmacogovernance and ultimately postmarket drug safety in a low and upper-middle income country (Kenya and Brazil); and how patterns of governance (e.g., devolved and decentralized) affect pharmacovigilance. A new application for ii Network Governance Theory is presented to explain state and non-state actors’ interactions regarding pharmacovigilance. Qualitative research methods that included key informant interviews, document analyses and a scoping review were conducted. Key findings show that the pharmacogovernance framework can guide policy making for postmarket drug safety. Policy, law and regulations are important for advancing pharmacovigilance and ensuring enforcement however gaps in other pharmacogovernance domains may impede pharmacovigilance in areas such as risk communication and regional equity in postmarket surveillance. The current funding model for pharmacovigilance in Brazil and Kenya is inadequate leading to ad hoc investment in pharmacovigilance and fluctuating priorities. Positive interdependency between pharmacogovernance structure, institutions and networks comprised of global actors can enhance pharmacogovernance and pharmacovigilance. Research results illuminate how in Brazil and Kenya investments in pharmacogovernance processes, institutions and network engagement may further improve pharmacovigilance. Investments include: strengthening medicines regulatory authorities; establishing a sustainable funding model for pharmacovigilance; strengthening social participation and inclusion in regulatory decisions pertaining to pharmacovigilance; and increasing interdependency amongst pharmacogovernance structure, institutions, and networks. iii Acknowledgments The journey to completing a doctorate is an arduous one made easier by a league of mentors, family and friends. I have many people to thank for the guidance and assistance they provided along my journey. First, I would like to thank my PhD supervisor Dr. Jillian C. Kohler, Advisory Committee members Dr. Joel Lexchin, Dr. Anita McGahan and Dr. Suzanne Cadarette who provided the mentorship and guidance that contributed to my success. I would also like to thank Dr. Barbara Mintzes, the external appraiser of my thesis for her thoughtful comments and Dr. Diana Menya, my research supervisor at Moi University, for enabling my research in Kenya. Next, I would like to thank my family for encouraging me throughout my journey. A special thank you goes to my husband Dr. Gervan Fearon who was instrumental in encouraging me to pursue a doctoral degree. He supported me in many ways during the past five years by accompanying me to late night study and writing sessions at coffee shops, reading numerous drafts of my thesis and providing constructive feedback. I would like to thank my sister Dr. Susan Moscou. Susie is the first person in my family to earn a PhD. She has been a fabulous mentor and role model. She set the bar for my family that we can pursue and achieve a doctoral degree. I am extremely proud of my daughter Dr. Gyasi Moscou-Jackson who received her PhD in nursing this past year. Gyasi and I enrolled in doctoral studies simultaneously. It has been an incredible mother-daughter bonding experience to walk this path together. While encouraging her and advising her through roadblocks in her doctoral journey, I have on occasion found that my words of advice were invaluable to me in overcoming similar setbacks. I would also like to thank my parents for encouraging their children to think about how to make a contribution to the betterment of society at large, thus influencing my decision to conduct research on pharmacogovernance. Lastly, I would like to that Dr. Paola Casalvina and João Batista Da Silva Junior for their contribution to the scoping review. iv Table of Contents Acknowledgments.......................................................................................................................... iv Table of Contents ...........................................................................................................................v List of Tables ...................................................................................................................................x List of Figures ................................................................................................................................ xi List of Appendices ........................................................................................................................ xii List of Abbreviations ................................................................................................................... xiv Chapter One: Introduction ...............................................................................................................1 1.1 Context .................................................................................................................................1 1.2 Background ..........................................................................................................................1 1.2.1 Postmarket drug safety issues in LMI countries ......................................................2 1.2.2 Pharmacovigilance in LMI countries .......................................................................5 1.2.3 Governance and postmarket drug safety ..................................................................6 1.2.4 Global actors and the spread of pharmacovigilance policy norms ..........................9 1.3 Statement of the problem ...................................................................................................10 1.3.1 Rationale for Examining Pharmacogovernance in LMI countries ........................10 1.3.2 Rationale for Investigating Pharmacogovernance in Brazil and Kenya ................11 1.3.3 Decentralization and devolved governance ...........................................................13 1.4 Rationale for the research ..................................................................................................13 1.5 Purpose of the research ......................................................................................................15 1.6 Theoretical Framework ......................................................................................................16 1.7 Overview of thesis chapters ...............................................................................................22 Chapter Two: Methods .................................................................................................................26 v 2.1 Preamble ............................................................................................................................26 2.2 Research Methods ..............................................................................................................26 2.2.1 Case Study .............................................................................................................27 2.3 Data Sources and Methods of Data Collection ..................................................................29 2.3.1 Semi-structured interviews ....................................................................................30 2.3.2 Documentary Evidence ..........................................................................................37 2.3.3 Scoping Review .....................................................................................................38 2.4 Data Analysis .....................................................................................................................40 2.4.1 Thematic Analysis .................................................................................................40 2.4.2 Semantic Analysis ..................................................................................................41 2.5 Validity and Reliability ......................................................................................................41
Load more

Recommended publications
  • Teaching Health Policy and Politics in U.S. Schools of Public Health
    Teaching Health Policy and Politics in U.S. Schools of Public Health DEBORAH R. McFARLANE and LARRY J. GORDON INTRODUCTION MOST public health activities in the United States are funded by the public sector. The American political system guarantees that public resources will arrive by circuitous routes. This political system is federal (meaning that federal, state, and local agencies are involved); it is partisan (meaning, among other things, that different players will present different versions of the facts); and it involves many institutions (meaning that policy processes are usually slow and have many steps). In spite of its imperfections, government is an important source of revenue for many public health programs. In order to secure these public resources, public health practitioners must be adept at working within the political system. The recent Institute of Medicine (IOM) study, The Future of Public Health, however, found that many public health professionals are ignorant or disdainful of political processes. In fact, many public health professionals do not even participate in activities that they perceive as political. This lack of involvement has very serious consequences. The Future o f Public Health reported that one result is that many public policymakers do not consider appropriate technical advice when they are developing health policies (1). About 3,500 public health professionals graduate each year from U.S. schools of public health (2). The IOM report stated that the purpose of public health education should be to train
    [Show full text]
  • CARIBBEAN PHARMACEUTICAL POLICY.Indd
    <PAHO DOCUMENTOC IDENTIFICATION No> Caribbean PharmaceuticalPolicy Caribbean Pharmaceutical Policy Caribbean Pharmaceutical Policy Washington, D.C., 2013 PAHO HQ Library Cataloguing-in-PublicaƟ on Data ************************************************************************ Pan American Health OrganizaƟ on. Caribbean Community. Caribbean PharmaceuƟ cal Policy. Washington, DC : PAHO, 2013. 1. Drug and NarcoƟ c Control. 2. Health Policy, Planning and Management. 3. NaƟ onal Drug Policy. 4. Caribbean. I. Title. II. CARICOM. ISBN 978-92-75-11807-8 (NLM classifi caƟ on: QV55) The Pan American Health OrganizaƟ on welcomes requests for permission to reproduce or trans- late its publicaƟ ons, in part or in full. ApplicaƟ ons and inquiries should be addressed to the Department of Knowledge Management and CommunicaƟ ons (KMC), Pan American Health OrganizaƟ on, Washington, D.C., U.S.A. ([email protected]). The Department of Health Systems and Services (HSS) will be glad to provide the latest informaƟ on on any changes made to the text, plans for new ediƟ ons, and reprints and translaƟ ons already available. © Pan American Health OrganizaƟ on, 2013. All rights reserved. PublicaƟ ons of the Pan American Health OrganizaƟ on enjoy copyright protecƟ on in accordance with the provisions of Protocol 2 of the Universal Copyright ConvenƟ on. All rights are reserved. The designaƟ ons employed and the presentaƟ on of the material in this publicaƟ on do not imply the expression of any opinion whatsoever on the part of the Secretariat of the Pan American Health Orga- nizaƟ on concerning the status of any country, territory, city or area or of its authoriƟ es, or concerning the delimitaƟ on of its fronƟ ers or boundaries.
    [Show full text]
  • Pharmaceutical Good Manufacturing Practice Regulatory Affairs in Sudan
    ulatory A eg ffa R i l rs a : c i O t p Abdellah Abubaker et al., Pharmaceut Reg Affairs u Pharmaceutical Regulatory Affairs: e e n c A a 2016, 5:1 c m c r e ISSN:a 2167-7689 s h DOI: 10.4172/2167-7689.1000166 s P Open Access Research Article Open Access Pharmaceutical Good Manufacturing Practice Regulatory Affairs in Sudan: Continuous Debate between Regulatory Authority and Manufacturers Abubaker Abdellah1*, M I Noordin2,3, R Zaki4 and Ali Abedallah5 1Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia 2Malaysian Institute of Pharmaceuticals and Nutraceuticals, Penang 3Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia 4Faculty of Medicine, Department of Social and Preventive medicine, University of Malaya, Kuala Lumpur, Malaysia 5Faculty of Science, Department of Chemistry, University of Khartoum, Sudan *Corresponding author: Abubaker Abdellah, Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia, Tel: +603-7967 5768; E-mail: [email protected] Received date: April 28, 2016; Accepted date: May 30, 2016; Published Date: June 01, 2016 Copyright: © 2016 Abubaker Abdellah et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Background: The implementation of GMP requirements in Sudan as developing country imposes pressure on both the manufacturers and regulatory authorities since resources are limited and additional regulatory and manufacturing facilities are required. Objective: The study aimed to assess the regulatory affairs of pharmaceutical good manufacturing practice in Sudan.
    [Show full text]
  • Jonas & Kovner's
    Knickman Jonas & Kovner’s 11th Edition Kovner Health Care Delivery in the United States Jonas & Kovner’s 11th James R. Knickman, PhD · Anthony R. Kovner, PhD Editors Edition Steven Jonas, MD, MPH, MS, FNYAS, Founding Editor Jonas & Kovner’s “Health care managers, practitioners, and students must both operate as efectively as they can within the daunting and con- tinually evolving system at hand and identify opportunities for reform advances… Health Care Delivery in the United States Health Care has been an indispensable companion to those preparing to manage this balance. Te present edition demonstrates once again why this volume has come to be so prized. It takes the long view – charting recent developments in health policy, and putting them side-by-side with descriptions and analysis of existing programs in the United States and abroad.” —Sherry Glied, PhD, Dean and Professor of Public Service, NYU Wagner, From the Foreword his fully updated and revised 11th edition of a highly esteemed survey and analysis of health care delivery in the Health Care Delivery in the United States keeps pace with the rapid changes that are reshaping our system. Fundamentally, this new edition Delivery Tpresents the realities that impact our nation’s achievement of the so-called Triple Aim: better health and better care at a lower cost. It addresses challenges and responses to the Afordable Care Act (ACA), the implementation of Obamacare, and many new models of care designed to replace outmoded systems. Leading scholars, practitioners, and educators within population health and medical care present the most up-to-date evidence-based information on health disparities, vulnerable populations, and immigrant health; nursing workforce challenges; new information technology; preventive medicine; emerging approaches to control health care costs; and much more.
    [Show full text]
  • China's Capacity to Manage Infectious Diseases
    China’s Capacity to Manage Infectious Diseases CENTER FOR STRATEGIC & Global Implications CSIS INTERNATIONAL STUDIES A Report of the CSIS Freeman Chair in China Studies 1800 K Street | Washington, DC 20006 PROJECT DIRECTOR Tel: (202) 887-0200 | Fax: (202) 775-3199 Charles W. Freeman III E-mail: [email protected] | Web: www.csis.org PROJECT EDITOR Xiaoqing Lu March 2009 ISBN 978-0-89206-580-6 CENTER FOR STRATEGIC & Ë|xHSKITCy065806zv*:+:!:+:! CSIS INTERNATIONAL STUDIES China’s Capacity to Manage Infectious Diseases Global Implications A Report of the CSIS Freeman Chair in China Studies PROJECT DIRECTOR Charles W. Freeman III PROJECT EDITOR Xiaoqing Lu March 2009 About CSIS In an era of ever-changing global opportunities and challenges, the Center for Strategic and Inter- national Studies (CSIS) provides strategic insights and practical policy solutions to decisionmak- ers. CSIS conducts research and analysis and develops policy initiatives that look into the future and anticipate change. Founded by David M. Abshire and Admiral Arleigh Burke at the height of the Cold War, CSIS was dedicated to the simple but urgent goal of finding ways for America to survive as a nation and prosper as a people. Since 1962, CSIS has grown to become one of the world’s preeminent public policy institutions. Today, CSIS is a bipartisan, nonprofit organization headquartered in Washington, D.C. More than 220 full-time staff and a large network of affiliated scholars focus their expertise on defense and security; on the world’s regions and the unique challenges inherent to them; and on the issues that know no boundary in an increasingly connected world.
    [Show full text]
  • Coronavirus Politics
    Coronavirus The Comparative Politics Politics and Policy of COVID-19 EDITED BY Scott L. Greer, Elizabeth J. King, Elize Massard da Fonseca, and André Peralta-Santos Coronavirus PolitiCs Coronavirus PolitiCs The Comparative Politics and Policy of COVID-19 Scott L. Greer, Elizabeth J. King, Elize Massard da Fonseca, and André Peralta-Santos, Editors University of Michigan Press ann arbor Copyright © 2021 by Scott L. Greer, Elizabeth J. King, Elize Massard da Fonseca, and André Peralta- Santos Some rights reserved This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 Interna- tional License. Note to users: A Creative Commons license is only valid when it is applied by the person or entity that holds rights to the licensed work. Works may contain components (e.g., photo graphs, illustrations, or quotations) to which the rightsholder in the work cannot apply the license. It is ultimately your responsibility to inde penden tly evaluate the copyright status of any work or component part of a work you use, in light of your intended use. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc/4.0/ For questions or permissions, please contact um . press . perms@umich . edu Published in the United States of Amer i ca by the University of Michigan Press Manufactured in the United States of Amer i ca Printed on acid-f ree paper First published April 2021 A CIP cata log rec ord for this book is available from the British Library. Library of Congress Cataloging-i n-P ublication data has been applied for.
    [Show full text]
  • How Information About Race-Based Health Disparities Affects Policy Preferences: Evidence from a Survey Experiment About the COVID-19 Pandemic in the United States
    How information about race-based health disparities affects policy preferences: Evidence from a survey experiment about the COVID-19 pandemic in the United States The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Harell, Allison and Evan Lieberman. "How information about race- based health disparities affects policy preferences: Evidence from a survey experiment about the COVID-19 pandemic in the United States." Social Science & Medicine 277 (May 2021): 113884 © 2021 The Authors As Published https://doi.org/10.1016/j.socscimed.2021.113884 Publisher Elsevier BV Version Final published version Citable link https://hdl.handle.net/1721.1/130527 Terms of Use Creative Commons Attribution-NonCommercial-NoDerivs License Detailed Terms http://creativecommons.org/licenses/by-nc-nd/4.0/ Social Science & Medicine 277 (2021) 113884 Contents lists available at ScienceDirect Social Science & Medicine journal homepage: http://www.elsevier.com/locate/socscimed How information about race-based health disparities affects policy preferences: Evidence from a survey experiment about the COVID-19 pandemic in the United States Allison Harell a, Evan Lieberman b,* a Universit´e du Qu´ebec a` Montr´eal, Canada b Massachusetts Institute of Technology, USA ARTICLE INFO ABSTRACT Keywords: In this article, we report on the results of an experimental study to estimate the effects of delivering information Race about racial disparities in COVID-19-related death rates. On the one hand, we find that such information led to Racial prejudice increased perception of risk among those Black respondents who lacked prior knowledge; and to increased Health politics support for a more concerted public health response among those White respondents who expressed favorable Health policy views towards Blacks at baseline.
    [Show full text]
  • Environmental Health COURSE NUMBER: 590R CLASS NUMBER
    DATE OF THIS DRAFT: 3/5/2019 3:48 PM DEPARTMENT: Environmental Health COURSE NUMBER: 590R CLASS NUMBER: 001 SEMESTER: S 2019 CREDIT HOURS: 2 TIME: 1:00-2:50pm Monday ROOM: GCR L35 Politics of Public Health COURSE TITLE: INSTRUCTOR NAME: Richard Doner TA NAME: Sabrina Haque INSTRUCTOR / TA CONTACT INFORMATION: [email protected] EMAIL: [email protected] PHONE: Richard Doner (404) 727-7914 SCHOOL ADDRESS / OFFICE LOCATION: Tarbutton Hall 304 OFFICE HOURS: TTh 3:30-5 and by appointment BRIEF COURSE DESCRIPTION: This course is designed to help students, as future public health practitioners, understand and anticipate the ways in which politics – defined as interests, power, and institutions – affect public health interventions. This is thus a course on “applied” politics, not one on environmental justice or the broader political determinants of health outcomes. The course is structured around key stages in the policy process: agenda setting, policy formulation and adoption, implementation and evaluation. Using cases drawn from a range of countries, supplemented by several guest speakers, the course will explore specific kinds of institutional and political bottlenecks, potential solutions, and generalizability of lessons learned from specific cases. Rollins Competencies • Assess the impact of context-specific political factors on the nature and outcomes of public health interventions EH Competencies • Explain major policy issues in Environmental Health as they emerge and are addressed in diverse socio-political contexts GEH Competencies
    [Show full text]
  • Pharmaceutical Policy in China
    Pharmaceutical policy in China Challenges and opportunities for reform Elias Mossialos, Yanfeng Ge, Jia Hu and Liejun Wang Pharmaceutical policy in China: challenges and opportunities for reform Pharmaceutical policy in China: challenges and opportunities for reform Elias Mossialos, Yanfeng Ge, Jia Hu and Liejun Wang London School of Economics and Political Science and Development Research Center of the State Council of China Keywords DRUG AND NARCOTIC CONTROL PHARMACEUTICAL PREPARATIONS DRUG COSTS DRUG INDUSTRY HEALTH CARE REFORM HEALTH POLICY CHINA © World Health Organization 2016 (acting as the host organization for, and secretariat of, the European Observatory on Health Systems and Policies) All rights reserved. The European Observatory on Health Systems and Policies welcomes requests for permission to reproduce or translate its publications, in part or in full. Address requests about publications to: Publications, WHO Regional Office for Europe, UN City, Marmorvej 51, DK-2100 Copenhagen Ø, Denmark. Alternatively, complete an online request form for documentation, health information, or for permission to quote or translate, on the Regional Office web site (www.euro.who.int/pubrequest). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the European Observatory on Health Systems and Policies concerning the legal status of any country, territory, city or area or of its authorities, or concern- ing the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the European Observatory on Health Systems and Policies in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • World Bank Document
    HNP Brief #3 Pharmaceuticals: Local Manufacturing March 2005 Public Disclosure Authorized Introduction These numbers would look different if units (tablets) were counted instead of sales value. Middle income Pharmaceuticals are essential in every health care countries with large populations would take up a much system. The objective of pharmaceutical policy is to larger share, based on large volume / low cost markets make sure that there is a reliable supply of good quality for drugs in these countries (unfortunately, reliable data medicines at affordable prices. Local manufacturing is are not available because these numbers are not very sometimes offered as a potential solution to the relevant for industry decision makers). The large home “access” problem. Supporters of this concept suggest market allows manufacturers in India and China to that local production in a developing country should produce at low unit cost and exploit economies of scale. result in a cheaper final product. Skeptics argue that Given that drugs can be moved easily around the globe, small manufacturing units don’t achieve economies of if there were no or few barriers to importing, registration, scale, and that higher unit costs outweigh potential marketing and distribution, presumably, it would be hard Public Disclosure Authorized advantages such as lower transportation costs.[1] to beat Indian and Chinese manufacturers on price (although there may be lower price manufacturers who Another factor in this discussion is the TRIPS do not meet quality standards). Any market analysis that agreement. TRIPS requires all countries (except the is done to establish the business case for least developed) to introduce patents for pharmaceutical local manufacturing should recognize pharmaceuticals in 2005.
    [Show full text]
  • The Seeds of Policy Change: Leveraging Diffusion to Disseminate Policy Innovations
    The Seeds of Policy Change: Leveraging Diffusion to Disseminate Policy Innovations Frederick J. Boehmke University of Iowa Abigail Matthews Rury University of Iowa Bruce A. Desmarais Pennsylvania State University Jeffrey J. Harden University of Notre Dame Abstract We conduct a series of simulations to compare how various strategies for seeding a policy in the American states affect the rate at which that policy spreads. Using empirically derived parameters of the policy diffusion process, we simulate the diffusion of a hypothetical policy after seeding the policy in just a handful of states. We compare these strategies to seeding the ten states the RWJF monitored during the states’ implementation of the Affordable Care Act of 2010. We attempt to mimic the choices that policy advocates make when deciding which states to target with their resources. Our results indicate that focusing on innovative states, that is, those that tend to adopt new policies faster, offers a valuable boost in the speed of diffusion. Even better, though, is a strategy that targets policy leaders. Keywords policy diffusion, policy advocacy, networks Introduction Should policy advocates spread their efforts equally across governing units, or focus on a few key jurisdictions? Faced with limited resources, advocates typically choose to pursue their case in a limited number of forums. Yet, they ultimately wish to influence policy as broadly as possible by seeding a cascade of policy adoption across jurisdictions beyond the The authors would like to thank participants at the 2015 Robert Wood Johnson Foundation Conference on Diffusion of ACA Policies Across the American States and comments received from the anonymous referees.
    [Show full text]
  • A Practical Approach to Pharmaceutical Policy. World
    Public Disclosure Authorized DIRECTIONS IN DEVELOPMENT Human Development Public Disclosure Authorized A Practical Approach to Pharmaceutical Policy Andreas Seiter Public Disclosure Authorized Public Disclosure Authorized APAPP_i-xxii.qxd 5/21/10 11:45 AM Page i A Practical Approach to Pharmaceutical Policy APAPP_i-xxii.qxd 5/21/10 11:45 AM Page ii APAPP_i-xxii.qxd 5/21/10 11:45 AM Page iii A Practical Approach to Pharmaceutical Policy Andreas Seiter APAPP_i-xxii.qxd 5/21/10 11:45 AM Page iv © 2010 The International Bank for Reconstruction and Development / The World Bank 1818 H Street NW Washington DC 20433 Telephone: 202-473-1000 Internet: www.worldbank.org E-mail: [email protected] All rights reserved 1 2 3 4 13 12 11 10 This volume is a product of the staff of the International Bank for Reconstruction and Development/ The World Bank. The findings, interpretations, and conclusions expressed in this volume do not nec- essarily reflect the views of the Executive Directors of The World Bank or the governments they rep- resent. The World Bank does not guarantee the accuracy of the data included in this work. The bound- aries, colors, denominations, and other information shown on any map in this work do not imply any judgement on the part of The World Bank concerning the legal status of any territory or the endorsement or acceptance of such boundaries. Rights and Permissions The material in this publication is copyrighted. Copying and/or transmitting portions or all of this work without permission may be a violation of applicable law.
    [Show full text]